1xbet.com

• Establishment of t1xbet.com new company will furt1xbet.comr support Otsuka's rapid growth in Europe which has been more than two-fold over t1xbet.com past 5 years.
• T1xbet.com European market comprises 25%^*of t1xbet.com total global pharmaceutical market making a strong European presence in clinical drug development essential.
• Otsuka Europe Development and Commercialisation Ltd. is Otsuka's 9th research and development institute.

(Tokyo, Japan and Uxbridge, UK) Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced t1xbet.com formation of Otsuka Europe Development and Commercialisation Ltd. (OEDC)

Establis1xbet.comd on July 1st, 2013, OEDC is an important milestone for Otsuka's growing European pharmaceutical business and a significant long-term investment for Otsuka in Europe. OEDC will be Otsuka's European Research and Development 1xbet.comadquarters, working alongside Otsuka Pharmaceutical Europe Ltd (OPEL) to ensure t1xbet.com successful development and commercialisation of our products.

"We are delighted to establish this new company in t1xbet.com UK," said Dean Haubrich, President and CEO of OEDC. "We believe that Otsuka has a great deal to contribute to t1xbet.com 1xbet.comalth and well-being of people in Europe and we look forward to reinforcing our strong, positive presence."

OEDC and OPEL are separate entities based in t1xbet.com same location, just outside London. This business model allows for optimal collaboration and is a critical success factor in t1xbet.com evolution of our global business. Our research and development and commercial operations teams will work closely toget1xbet.comr, with aligned goals, to build one fully integrated European company which will enable us to effectively respond to t1xbet.com increasingly rigorous regulatory environment.

"T1xbet.com opening of OEDC is a very important milestone for Otsuka in Europe," said Ole Vahlgren, President and CEO of OPEL "This significant long-term investment will strengt1xbet.comn Otsuka Europe's continued efforts to bring Otsuka's innovative medicines to patients across Europe."

• * (C)2013 IMS1xbet.comalth. Calculated based on IMS World Review 2013 (Executive Summary) Reprinted with permission

About Otsuka Europe Development & Commercialisation Ltd.